Lupus Tumidus with Severe or Disseminated CLE Skin Lesions — Next Step After Mycophenolate Mofetil Did Not Achieve Disease Control

This protocol is for patients with lupus tumidus presenting as severe or disseminated cutaneous lupus erythematosus (CLE) skin lesions, where the preceding treatment line failed to achieve the target improvement of CLE disease activity within 3–6 months.

Clinical Scenario

Severe or disseminated cutaneous lupus erythematosus skin lesions. Antimalarial drugs are recommended as first-line and long-term treatment in all CLE patients with severe and disseminated skin lesions — particularly where there is a risk of scarring. Systemic glucocorticoids are recommended alongside antimalarial drugs as first-line treatment for a limited period in this setting.

Previous Treatment Line — Target Not Reached

The prior regimen — mycophenolate mofetil or mycophenolic acid, preferably in combination with antimalarial drugs — did not achieve the defined target: improvement of CLE disease activity after 3–6 months of treatment. This protocol describes the structured next step taken after that failure.

Next-Line Approach (Partial Overview)

The next-line protocol for this situation involves consideration of further systemic agents — spanning immunomodulatory drugs and biologic therapies — typically used in combination with antimalarial drugs. The complete protocol specifies which agents apply, in what clinical context, and with what monitoring requirements.

Treatment target: improvement of cutaneous lupus erythematosus disease activity after 3–6 months of treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14491

Antimalarial drugs are recommended as first-line treatments, also for long-term therapy, in all CLE patients with severe and disseminated skin lesions; in particular for patients with a risk of scarring.

For severe or disseminated CLE lesions, systemic glucocorticoids are recommended as first-line treatment in addition to antimalarial drugs, for a limited period of time.

Thalidomide may be considered in selected cases of refractory CLE lesions, preferably in combination with antimalarial drugs.

Belimumab may be considered for CLE treatment.

Rituximab may be considered for CLE treatment.

IVIG may be considered for treatment of CLE.

Azathioprine may be considered for treating CLE.

Ciclosporin may be considered for treating CLE.

It is recommended to evaluate the efficacy of systemic treatment for CLE after a minimum of three months and a maximum of six months (except for glucocorticoids).

View source ↗